UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 1-U
Current Report Pursuant to Regulation A
Date of Report: January 3, 2020
(Date of earliest event reported)
Commission File No. 024-10924
CANNABINOID BIOSCIENCES, INC. |
California
(State or other jurisdiction of incorporation or organization)
Cannabinoid Biosciences, Inc.
370 Amapola Ave., Suite 200A
Torrance, California 90501
(323) 868-6762; (310) 895-1839
franklin@cbdxfund.com
(Address, including zip code, and telephone number,
including area code, of issuer’s principal executive office)
Patience C Ogbozor
370 Amapola Ave., Suite 200A
Torrance, California 90501
Telephone: (310) 895-1839
cannabinoidbiosciences@gmail.com
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
Copy to:
Azuka L Uzoh, Esq.
Law Office of Azuka L Uzoh
1930 Wilshire Blvd., Suite 1216
Los Angeles, California 90025
Telephone: (213) 483-4020
2834 | 47-1077576 |
(Primary Standard Industrial | (IRS Employer |
Classification Code Number) | Identification Number) |
ITEM 9. | OTHER EVENTS |
LETTER OF INTENT TO ACQUIRE 5 2018 FARM BILL COMPLIANT CBD OPERATIONS
On January 6, 2020, the Company issued a press release announcing it has executed five game changing non-binding letter of intent (LOI) with five CBD operations in Michigan, North Carolina, Colorado, Kentucky and Nevada to acquire their Hemp cultivation and CBD manufacturing operations. A copy of the press release is filed and attached hereto as Exhibit 6.2.
Safe Harbor Statement
This Current Report on Form 1-U contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934. You can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “projects,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties, including those described under the section entitled “Risk Factors” in our Offering Statement on Form 1-A, filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in our periodic filings and prospectus supplements filed with the SEC, which are accessible on the SEC’s website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our filings with the SEC. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
Exhibit No. |
| Description |
6.2 |
| Press release dated January 6, 2020 |
SIGNATURES
Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized in the Los Angeles, State of California, on January 6, 2020
Cannabinoid Biosciences, Inc.
By: | /s/ Frank I Igwealor |
Name: Frank I Igwealor, CPA, CMA, JD, MBA | |
Title: Sr. Vice President and Chief Financial Officer | |
